Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway

Osteoarthritis (OA) is the most common degenerative arthritis associated with pain and cartilage destruction in the elderly; it is known to be involved in inflammation as well. A drug called celecoxib is commonly used in patients with osteoarthritis to control pain. Metformin is used to treat type 2...

Full description

Bibliographic Details
Main Authors: Hyun Sik Na, Ji Ye Kwon, Seon-Yeong Lee, Seung Hoon Lee, A Ram Lee, Jin Seok Woo, KyungAh Jung, Keun-Hyung Cho, Jeong-Won Choi, Dong Hwan Lee, Hong-Ki Min, Sung-Hwan Park, Seok Jung Kim, Mi-La Cho
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/10/3/681
id doaj-e5008faea95e46dc91b759f0ab4f943b
record_format Article
spelling doaj-e5008faea95e46dc91b759f0ab4f943b2021-03-20T00:04:20ZengMDPI AGCells2073-44092021-03-011068168110.3390/cells10030681Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal PathwayHyun Sik Na0Ji Ye Kwon1Seon-Yeong Lee2Seung Hoon Lee3A Ram Lee4Jin Seok Woo5KyungAh Jung6Keun-Hyung Cho7Jeong-Won Choi8Dong Hwan Lee9Hong-Ki Min10Sung-Hwan Park11Seok Jung Kim12Mi-La Cho13The Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaImpact Biotech, Korea 505 Banpo-Dong, Seocho-Ku, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Orthopedic Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 11765, KoreaDivision of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul 05030, KoreaDivision of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Orthopedic Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 11765, KoreaThe Rheumatism Research Center, Catholic Reasearch Institute of Medical Science, The Catholic University of Korea, Seoul 06591, KoreaOsteoarthritis (OA) is the most common degenerative arthritis associated with pain and cartilage destruction in the elderly; it is known to be involved in inflammation as well. A drug called celecoxib is commonly used in patients with osteoarthritis to control pain. Metformin is used to treat type 2 diabetes but also exhibits regulation of the autophagy pathway. The purpose of this study is to investigate whether metformin can treat monosodium iodoacetate (MIA)-induced OA in rats. Metformin was administered orally every day to rats with OA. Paw-withdrawal latency and threshold were used to assess pain severity. Cartilage damage and pain mediators in dorsal root ganglia were evaluated by histological analysis and a scoring system. Relative mRNA expression was measured by real-time PCR. Metformin reduced the progression of experimental OA and showed both antinociceptive properties and cartilage protection. The combined administration of metformin and celecoxib controlled cartilage damage more effectively than metformin alone. In chondrocytes from OA patients, metformin reduced catabolic factor gene expression and inflammatory cell death factor expression, increased LC3Ⅱb, p62, and LAMP1 expression, and induced an autophagy–lysosome fusion phenotype. We investigated if metformin treatment reduces cartilage damage and inflammatory cell death of chondrocytes. The results suggest the potential for the therapeutic use of metformin in OA patients based on its ability to suppress pain and protect cartilage.https://www.mdpi.com/2073-4409/10/3/681osteoarthritismetforminpaincartilageautophagycombination therapy
collection DOAJ
language English
format Article
sources DOAJ
author Hyun Sik Na
Ji Ye Kwon
Seon-Yeong Lee
Seung Hoon Lee
A Ram Lee
Jin Seok Woo
KyungAh Jung
Keun-Hyung Cho
Jeong-Won Choi
Dong Hwan Lee
Hong-Ki Min
Sung-Hwan Park
Seok Jung Kim
Mi-La Cho
spellingShingle Hyun Sik Na
Ji Ye Kwon
Seon-Yeong Lee
Seung Hoon Lee
A Ram Lee
Jin Seok Woo
KyungAh Jung
Keun-Hyung Cho
Jeong-Won Choi
Dong Hwan Lee
Hong-Ki Min
Sung-Hwan Park
Seok Jung Kim
Mi-La Cho
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway
Cells
osteoarthritis
metformin
pain
cartilage
autophagy
combination therapy
author_facet Hyun Sik Na
Ji Ye Kwon
Seon-Yeong Lee
Seung Hoon Lee
A Ram Lee
Jin Seok Woo
KyungAh Jung
Keun-Hyung Cho
Jeong-Won Choi
Dong Hwan Lee
Hong-Ki Min
Sung-Hwan Park
Seok Jung Kim
Mi-La Cho
author_sort Hyun Sik Na
title Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway
title_short Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway
title_full Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway
title_fullStr Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway
title_full_unstemmed Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway
title_sort metformin attenuates monosodium-iodoacetate-induced osteoarthritis via regulation of pain mediators and the autophagy–lysosomal pathway
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2021-03-01
description Osteoarthritis (OA) is the most common degenerative arthritis associated with pain and cartilage destruction in the elderly; it is known to be involved in inflammation as well. A drug called celecoxib is commonly used in patients with osteoarthritis to control pain. Metformin is used to treat type 2 diabetes but also exhibits regulation of the autophagy pathway. The purpose of this study is to investigate whether metformin can treat monosodium iodoacetate (MIA)-induced OA in rats. Metformin was administered orally every day to rats with OA. Paw-withdrawal latency and threshold were used to assess pain severity. Cartilage damage and pain mediators in dorsal root ganglia were evaluated by histological analysis and a scoring system. Relative mRNA expression was measured by real-time PCR. Metformin reduced the progression of experimental OA and showed both antinociceptive properties and cartilage protection. The combined administration of metformin and celecoxib controlled cartilage damage more effectively than metformin alone. In chondrocytes from OA patients, metformin reduced catabolic factor gene expression and inflammatory cell death factor expression, increased LC3Ⅱb, p62, and LAMP1 expression, and induced an autophagy–lysosome fusion phenotype. We investigated if metformin treatment reduces cartilage damage and inflammatory cell death of chondrocytes. The results suggest the potential for the therapeutic use of metformin in OA patients based on its ability to suppress pain and protect cartilage.
topic osteoarthritis
metformin
pain
cartilage
autophagy
combination therapy
url https://www.mdpi.com/2073-4409/10/3/681
work_keys_str_mv AT hyunsikna metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT jiyekwon metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT seonyeonglee metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT seunghoonlee metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT aramlee metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT jinseokwoo metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT kyungahjung metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT keunhyungcho metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT jeongwonchoi metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT donghwanlee metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT hongkimin metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT sunghwanpark metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT seokjungkim metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
AT milacho metforminattenuatesmonosodiumiodoacetateinducedosteoarthritisviaregulationofpainmediatorsandtheautophagylysosomalpathway
_version_ 1724212505436225536